

# News Release

## News Release

Contact Andrew Bright  
+1 (484) 530 3922  
[andrew.bright@oncure.com](mailto:andrew.bright@oncure.com)  
[www.oncure.com](http://www.oncure.com)

### **ONCURE™ Announces French Reimbursement for Their Leading Prostate Cancer Treatment Products.**

Paris, June 7th, 2005 - ONCURE, a global leader in the minimally invasive management of prostate cancer announces the recent establishment of reimbursement in France for its prostate brachytherapy products; RAPID Strand™, EchoSeed™ and OncoSeed™.

Prostate brachytherapy consists of the permanent placement of radioactive seeds in the prostate. The seeds are about the size of a grain of rice and once in the prostate provide therapeutic radiation to treat the cancer, with minimal impact on surrounding parts of the body. This is unlike other treatment options such as external radiation, where the prostate and surrounding tissue receive multiple radiation treatments from different directions, or radical surgery where the prostate is removed during an operation.

ONCURE's brachytherapy products have been extensively used over the last 15 years, with numerous scientific studies demonstrating long term effectiveness, as well as a low level of side effects when compared to other treatment options, especially surgery with its higher level of impotence. In 2004 only several hundred French patients received prostate brachytherapy in a limited number of institutions, while around 40,000 new cases of prostate cancer are diagnosed in France each year.

"The establishment of reimbursement for this proven prostate cancer treatment is excellent for French men diagnosed with prostate cancer and looking for a minimally invasive treatment option," explained Elizabeth Usher, Vice President and General Manager of ONCURE's International division. She added, "There are excellent institutions in France who have experience with prostate brachytherapy, as well as physicians well trained to perform the procedure. ONCURE is proud to have contributed to the successful establishment of prostate brachytherapy in France".

ONCURE was created through the merger of Amersham plc's brachytherapy business and Galil Medical Ltd's urology business. Galil is a subsidiary of Elron (ELRN). Headquartered in the United States, ONCURE operates as an independent business, with a major presence in the treatment of prostate cancer. ONCURE's International business is operated from its UK subsidiary. On April 8, 2004, General Electric (GE) completed its previously announced acquisition of Amersham.